Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 mild to moderate meta-analysis

CORIMUNO-19, 2020
RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
64/67 inconclusive -7% -39%
RCTtocilizumab placeboCOVID-19 mild to moderatesome concern
259/129 conclusif 12% 13% demonstrated-40%
Capra, 2020 OBStocilizumab controlCOVID-19 mild to moderatecritical
62/23 suggested -87%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).